Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
[EN] THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE THIÉNOPYRIMIDIÈNE COMME INHIBITEURS DE PI3K
申请人:HOFFMANN LA ROCHE
公开号:WO2009053715A8
公开(公告)日:2010-06-03
THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS
申请人:F. Hoffmann-La Roche AG
公开号:EP2205610A1
公开(公告)日:2010-07-14
US8293735B2
申请人:——
公开号:US8293735B2
公开(公告)日:2012-10-23
THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS
申请人:Hancox Timothy Colin
公开号:US20110021496A1
公开(公告)日:2011-01-27
Thienopyrimidines of formula (I) wherein W and R
1
to R
4
are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.